A panel of sarcoma cells, including SJSA cells, as well as CRL-304328, CRL-304428 and GOT-329 (the latter three derived from well-differentiated liposarcoma and with amplifications of CDK4 and MDM2 genes), were treated with Palbociclib to inhibit CDK4, as well as Nutlin to block the MDM2–p53 interaction. Here, CDK4 is linked to sarcoma.